Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P20807

UPID:
CAN3_HUMAN

ALTERNATIVE NAMES:
Calcium-activated neutral proteinase 3; Calpain L3; Calpain p94; Muscle-specific calcium-activated neutral protease 3; New calpain 1

ALTERNATIVE UPACC:
P20807; A6H8K6; Q7L4R0; Q9BQC8; Q9BTU4; Q9Y5S6; Q9Y5S7

BACKGROUND:
The protein Calpain-3, known by alternative names such as Calpain L3 and muscle-specific calcium-activated neutral protease 3, is crucial for muscle integrity and cellular signaling, mediated by its protease activity on specific substrates like CTBP1 and p53/TP53.

THERAPEUTIC SIGNIFICANCE:
Given its association with autosomal recessive and dominant forms of limb-girdle muscular dystrophy, Calpain-3 represents a promising target for therapeutic intervention. Exploring its function further could unveil new pathways for treating these debilitating muscle diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.